8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

April 20, 2010

(Exact name of registrant as specified in its charter)

New Jersey	I-3215	22-1024240
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933

(Address of Principal Executive Offices)

 (Zip Code)

Registrant’s telephone number, including area code:

732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17

               CFR 240.14d-2(b))

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

               CFR 240.13e-4(c))

Item 2.02                      Results of Operations and Financial Condition

On April 20, 2010, Johnson & Johnson issued the attached press release announcing its sales and earnings for the first quarter ended April 4, 2010.

Item 9.01            Financial Statements and Exhibits

Exhibit No.	Description of Exhibit
99.15	Press Release dated April 20, 2010 for the period ended April 4, 2010.
99.2O	Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the first quarter.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Johnson & Johnson
		(Registrant)
Date: April 20, 2010	By:	/s/ Stephen J. Cosgrove
		Stephen J. Cosgrove Controller (Principal Accounting Officer)

EX-99.15 OTH FIN ST

Exhibit 99.15

Johnson & Johnson Reports 2010 First-Quarter Results:

Sales of $15.6 Billion Increased 4.0% Versus 2009 First-Quarter; EPS was $1.62

 Excluding Special Items, 2010 First-Quarter EPS was $1.29, an increase of 2.4%*

New Brunswick, NJ (April 20, 2010) – Johnson & Johnson today announced sales of $15.6 billion for the first quarter of 2010, an increase of 4.0% as compared to the first quarter of 2009. Operational results declined 0.1% and the positive impact of currency was 4.1%.  Domestic sales declined 5.0%, while international sales increased 14.4%, reflecting operational growth of 5.5% and a positive currency impact of 8.9%.

Net earnings and diluted earnings per share for the first quarter of 2010 were $4.5 billion and $1.62, respectively. First quarter 2010 net earnings included an after-tax gain of $910 million representing the net impact of litigation matters. Excluding this special item, net earnings for the current quarter were $3.6 billion and diluted earnings per share were $1.29, representing increases of 3.1% and 2.4%, respectively, as compared to the same period in 2009.*   The Company updated its earnings guidance for full-year 2010 to $4.80 - $4.90 per share to reflect recent changes in foreign currency exchange rates. Earnings guidance excludes the impact of special items and now incorporates the impact of recently enacted health care reform legislation.

“Thanks to the outstanding efforts of our people, we were able to deliver solid financial results,” said William C. Weldon, Chairman and Chief Executive Officer. “This was accomplished despite a major product recall and the continued impact of patent expirations. We are well positioned for future growth.”

Worldwide Consumer sales of $3.8 billion for the first quarter represented an increase of 1.5% versus the prior year consisting of a decrease of 3.7% operationally and a positive impact from currency of 5.2%. Domestic sales decreased 9.6%; international sales increased 11.1%, which reflected an operational increase of 1.4% and a positive currency impact of 9.7%.

Positive contributors to operational results were NEUTROGENA®, AVEENO® and LE PETIT MARSEILLAIS® skin care products; ZYRTEC® over-the-counter allergy treatment; international sales of LISTERINE® antiseptic mouthrinse; and women’s sanitary protection products.   These operational sales increases were more than offset by the impact of the previously announced recall of selected OTC products as well as the devaluation of the Venezuelan currency.

Worldwide Pharmaceutical sales of $5.6 billion for the first quarter represented a decrease of 2.5% versus the prior year consisting of an operational decline of 5.7% and a positive impact from currency of 3.2%. Domestic sales decreased 12.7%; international sales increased 15.5%, which reflected an operational increase of 6.6% and a positive currency impact of 8.9%.

Products with strong operational growth included REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PREZISTA® (darunavir), a treatment for HIV; VELCADE® (bortezomib), a treatment for multiple myeloma; and international sales of  RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment, an antipsychotic medication. Strong growth was also achieved from newly launched products including STELARATM (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; and SIMPONITM (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Sales results of TOPAMAX® (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL® (risperidone), an antipsychotic medication, were negatively impacted by generic competition.

Worldwide Medical Devices and Diagnostics sales of $6.2 billion for the first quarter represented an increase of 12.5% versus the prior year consisting of an operational increase of 8.1% and a positive currency impact of 4.4%. Domestic sales increased 8.8%; international sales increased 15.9%, which reflected an operational increase of 7.5% and a positive currency impact of 8.4%.

Primary contributors to operational growth included Ethicon’s surgical care products; DePuy’s orthopaedic joint reconstruction and sports medicine businesses; Ethicon Endo-Surgery’s minimally invasive products and Advanced Sterilization Products’ infection prevention solutions; and Ortho-Clinical Diagnostics’ professional products. This growth was partially offset by lower sales in the Cordis franchise, reflecting continued competition in the drug-eluting stent market.

During the quarter, the Company filed for CE Mark in Europe for its NEVO® Sirolimus-Eluting Coronary Stent, the first drug-eluting stent to utilize RES TECHNOLOGY™ , eliminating the need for surface coated and permanent polymers.

About Johnson & Johnson

Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 114,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

*Net earnings and diluted earnings per share excluding special items, such as the net impact of litigation gains, are non-GAAP financial measures and should not be considered replacements for GAAP results. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measure can be found in the Investor Relations section of the Company’s website at www.jnj.com.

NOTE TO INVESTORS

Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm.  These schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's website at www.jnj.com

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections.  Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.  ; A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2010.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)

EX-99.2O OTH FIN ST

Exhbiti 99.2O

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)	FIRST QUARTER
	2010						2009						Percent
				Percent						Percent			Increase
	Amount			to Sales			Amount			to Sales			(Decrease)
Sales to customers		$        15,631			100.0			$        15,026			100.0			4.0
Cost of products sold		4,528			29.0			4,251			28.3			6.5
Selling, marketing and administrative expenses		4,779			30.5			4,608			30.7			3.7
Research expense		1,557			10.0			1,518			10.1			2.6
Interest (income)expense, net		81			0.5			81			0.5
Other (income)expense, net		(1,594	)		(10.2	)		(75)			(0.5	)
Earnings before provision for taxes on income		6,280			40.2			4,643			30.9			35.3
Provision for taxes on income		1,754			11.2			1,136			7.6			54.4
Net earnings		$          4,526			29.0			$          3,507			23.3			29.1
Net earnings per share  (Diluted)		$            1.62						$            1.26						28.6
Average shares outstanding  (Diluted)		2,797.3						2,789.8
Effective tax rate		27.9	%					24.5	%
Adjusted earnings before provision for taxes and net earnings(A)
Earnings before provision for taxes on income		$          4,783	(1)		30.6			$          4,643			30.9			3.0
Net earnings		$          3,616	(1)		23.1			$          3,507			23.3			3.1
Net earnings per share  (Diluted)		$            1.29	(1)					$            1.26						2.4
Effective tax rate		24.4	%					24.5	%
(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings
per share (diluted) is the exclusion of income from net litigation of $1,497 million, $910 million and $0.33 per share, respectively.

(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, they may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as business development, strategic developments (including restructuring and product line changes), significant litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, merger-related or other restructuring charges, or amortization of purchased intangibles, and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)		FIRST QUARTER
						Percent Change
		2010		2009		Total			Operations			Currency
Sales to customers by
segment of business
Consumer
U.S.	$		1,560		1,726		(9.6	) %		(9.6	)		-
International			2,206		1,985		11.1			1.4			9.7
			3,766		3,711		1.5			(3.7	)		5.2
Pharmaceutical
U.S.			3,206		3,674		(12.7	)		(12.7	)		-
International			2,432		2,106		15.5			6.6			8.9
			5,638		5,780		(2.5	)		(5.7	)		3.2
Med Devices & Diagnostics
U.S.			2,886		2,652		8.8			8.8			-
International			3,341		2,883		15.9			7.5			8.4
			6,227		5,535		12.5			8.1			4.4
U.S.			7,652		8,052		(5.0	)		(5.0	)		-
International			7,979		6,974		14.4			5.5			8.9
Worldwide		$	15,631		15,026		4.0	%		(0.1	)		4.1

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)	FIRST QUARTER
					Percent Change
	2010		2009		Total			Operations			Currency
Sales to customers by
geographic area
U.S.	$	7,652		8,052		(5.0	) %		(5.0	)		-
Europe		4,102		3,671		11.7			4.6			7.1
Western Hemisphere excluding U.S.		1,280		1,062		20.5			3.5			17.0
Asia-Pacific, Africa		2,597		2,241		15.9			7.8			8.1
International		7,979		6,974		14.4			5.5			8.9
Worldwide	$	15,631		15,026		4.0	%		(0.1	)		4.1

	REPORTED SALES vs. PRIOR PERIOD
		$MM
		FIRST QUARTER
				% Change
		2010	2009	Reported	Operational (1)	Currency
CONSUMER SEGMENT (2)
SKIN CARE
US		452	423	6.9%	6.9%	-
Intl		468	419	11.7%	2.4%	9.3%
WW		920	842	9.3%	4.6%	4.7%
BABY CARE
US		103	102	1.0%	1.0%	-
Intl		426	387	10.1%	1.2%	8.9%
WW		529	489	8.2%	1.2%	7.0%
ORAL CARE
US		174	188	(7.4%)	(7.4%)	-
Intl		207	177	16.9%	5.1%	11.8%
WW		381	365	4.4%	(1.3%)	5.7%
OTC/NUTRITIONALS
US		542	726	(25.3%)	(25.3%)	-
Intl		665	622	6.9%	(2.7%)	9.6%
WW		1,207	1,348	(10.5%)	(15.0%)	4.5%
WOMEN'S HEALTH
US		146	149	(2.0%)	(2.0%)	-
Intl		323	274	17.9%	7.8%	10.1%
WW		469	423	10.9%	4.4%	6.5%
WOUND CARE/OTHER
US		143	138	3.6%	3.6%	-
Intl		117	106	10.4%	-	10.4%
WW		260	244	6.6%	2.1%	4.5%
TOTAL CONSUMER
US		1,560	1,726	(9.6%)	(9.6%)	-
Intl		2,206	1,985	11.1%	1.4%	9.7%
WW		3,766	3,711	1.5%	(3.7%)	5.2%
Note: See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD
	$MM
	FIRST QUARTER
			% Change
	2010	2009	Reported	Operational (1)	Currency

PHARMACEUTICAL SEGMENT  (2) (5)

ACIPHEX/PARIET
US	119	138	(13.8%)	(13.8%)	-
Intl	141	125	12.8%	3.1%	9.7%
WW	260	263	(1.1%)	(5.7%)	4.6%
CONCERTA
US	231	269	(14.1%)	(14.1%)	-
Intl	98	75	30.7%	17.3%	13.4%
WW	329	344	(4.4%)	(7.3%)	2.9%
DURAGESIC/FENTANYL TRANSDERMAL
US	38	75	(49.3%)	(49.3%)	-
Intl	146	156	(6.4%)	(13.4%)	7.0%
WW	184	231	(20.3%)	(25.1%)	4.8%
LEVAQUIN/FLOXIN
US	363	408	(11.0%)	(11.0%)	-
Intl	8	17	(52.9%)	(56.3%)	3.4%
WW	371	425	(12.7%)	(12.8%)	0.1%
PREZISTA
US	89	72	23.6%	23.6%	-
Intl	98	50	96.0%	80.3%	15.7%
WW	187	122	53.3%	46.8%	6.5%
PROCRIT/EPREX
US	290	321	(9.7%)	(9.7%)	-
Intl	233	229	1.7%	(6.2%)	7.9%
WW	523	550	(4.9%)	(8.2%)	3.3%
REMICADE
US	780	737	5.8%	5.8%	-
US Exports (3)	400	286	39.9%	39.9%	-
Intl	6	5	20.0%	19.9%	0.1%
WW	1,186	1,028	15.4%	15.4%	-

Note: See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD
	$MM
	FIRST QUARTER
			% Change
	2010	2009	Reported	Operational (1)	Currency

PHARMACEUTICAL SEGMENT  (2) (5) (Continued)

RISPERDAL/RISPERIDONE
US	5	118	(95.8%)	(95.8%)	-
Intl	133	157	(15.3%)	(20.1%)	4.8%
WW	138	275	(49.8%)	(52.5%)	2.7%
RISPERDAL CONSTA
US	117	126	(7.1%)	(7.1%)	-
Intl	262	199	31.7%	21.4%	10.3%
WW	379	325	16.6%	10.3%	6.3%
TOPAMAX
US	57	495	(88.5%)	(88.5%)	-
Intl	91	107	(15.0%)	(21.6%)	6.6%
WW	148	602	(75.4%)	(76.6%)	1.2%
VELCADE
US	-	-	-	-	-
Intl	261	192	35.9%	26.3%	9.6%
WW	261	192	35.9%	26.3%	9.6%
OTHER
US	717	629	14.0%	14.0%	-
Intl	955	794	20.3%	11.1%	9.2%
WW	1,672	1,423	17.5%	12.4%	5.1%
TOTAL PHARMACEUTICAL
US	3,206	3,674	(12.7%)	(12.7%)	-
Intl	2,432	2,106	15.5%	6.6%	8.9%
WW	5,638	5,780	(2.5%)	(5.7%)	3.2%
MAJOR NEW PHARMACEUTICAL PRODUCTS (4)
INVEGA
US	69	66	4.5%	4.5%	-
Intl	39	25	56.0%	43.2%	12.8%
WW	108	91	18.7%	15.1%	3.6%

Note: See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD
	$MM
	FIRST QUARTER
			% Change
	2010	2009	Reported	Operational (1)	Currency

MEDICAL DEVICES AND DIAGNOSTICS   (2)

CORDIS (6)
US	251	246	2.0%	2.0%	-
Intl	421	422	(0.2%)	(6.3%)	6.1%
WW	672	668	0.6%	(3.3%)	3.9%
DEPUY
US	814	766	6.3%	6.3%	-
Intl	640	526	21.7%	11.2%	10.5%
WW	1,454	1,292	12.5%	8.2%	4.3%
DIABETES CARE
US	290	270	7.4%	7.4%	-
Intl	307	271	13.3%	5.4%	7.9%
WW	597	541	10.4%	6.4%	4.0%
ETHICON
US	510	405	25.9%	25.9%	-
Intl	637	548	16.2%	7.6%	8.6%
WW	1,147	953	20.4%	15.5%	4.9%
ETHICON ENDO-SURGERY
US	483	454	6.4%	6.4%	-
Intl	685	561	22.1%	12.9%	9.2%
WW	1,168	1,015	15.1%	10.0%	5.1%
ORTHO-CLINICAL DIAGNOSTICS
US	288	277	4.0%	4.0%	-
Intl	237	190	24.7%	16.1%	8.6%
WW	525	467	12.4%	8.9%	3.5%
VISION CARE
US	249	234	6.4%	6.4%	-
Intl	415	365	13.7%	6.9%	6.8%
WW	664	599	10.9%	6.8%	4.1%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US	2,886	2,652	8.8%	8.8%	-
Intl	3,341	2,883	15.9%	7.5%	8.4%
WW	6,227	5,535	12.5%	8.1%	4.4%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported in U.S. sales

(4) Included in Other

(5) Prior year conforms to current presentation

(6) Includes sales of Drug-Eluting Stents for Q1 2010 of $60, $131 and $191MM Domestic, International and Worldwide, respectively

      Includes sales of Drug-Eluting Stents for Q1 2009 of $67, $184 and $251MM Domestic, International and Worldwide, respectively